Add like
Add dislike
Add to saved papers

Q&A: Gordon Mills on Neomorphs in Cancer.

Cancer Discovery 2016 October
Gordon Mills, MD, PhD, chair of systems biology at The University of Texas MD Anderson Cancer Center in Houston, discusses a third category of genomic aberrations besides oncogene activation or tumor suppressor inactivation: neomorphs, or mutations that rewire cellular signaling in unexpected ways, with important functional consequences.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app